What are the effects of orally administered alpha-lipoic acid (ALA) compared to a placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN), and what is the optimal dosage?
Alpha-Lipoic Acid, a meta-analysis in 1242 patients (Nutrients 2023, PMID 37630823) — oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater effect on some outcomes. Scope: 1242 patients, and the abstract states no limitations.
Source: Nutrients 2023, PMID 37630823 ↗ · Research map · How Magellan grades evidence · evidence confidence: low
Nutrients · 2023 · PMID 37630823 · DOI 10.3390/nu15163634
Oral alpha-lipoic acid may reduce sensory symptoms and improve global satisfaction in diabetic neuropathy patients, with higher doses showing a greater effect on some outcomes.
The question
What are the effects of orally administered alpha-lipoic acid (ALA) compared to a placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN), and what is the optimal dosage?
What they tested
The researchers hypothesized that oral ALA would improve symptoms in DSPN patients by reducing oxidative stress and improving microcirculation, and they aimed to determine an optimal dosage.
How they did it
A meta-analysis of ten randomized controlled trials (RCTs) involving 1242 patients was conducted. The studies were retrieved from PubMed, Embase, and Cochrane databases. Primary outcome was total symptoms' score (TSS), and secondary outcomes included neurological disability score (NDS), neuropathy impaired score (NIS), NIS-lower limb (NIS-LL), vibration perception threshold (VPT), nerve conduction study (NCS) results, and global satisfaction. A subgroup analysis was performed for ALA dosages of 600, 1200, and 1800 mg/day.
What they found
ALA treatment showed favorable results for total symptoms' score (TSS), neurological disability score (NDS), and global satisfaction score. A dose-related trend was observed for TSS and global satisfaction. However, ALA did not produce favorable results for VAS, VPT, NIS-LL, and NCS results.
What it means
Oral ALA treatment has favorable effects on DSPN by reducing sensory symptoms, with a dose-dependent response observed for TSS and global satisfaction score. Further research is needed to investigate the use of ALA for preventing neurological symptoms.
Limitations
The abstract does not explicitly state limitations of the meta-analysis itself, but it suggests that further research is needed to investigate ALA's role in preventing neurological symptoms.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Magellan’s evidence label | universal antioxidant, glucose metabolism (our label for this citation — see PubMed for the paper’s own title and authors) |
|---|---|
| Journal | Nutrients |
| Year | 2023 |
| PMID | 37630823 ↗ |
| DOI | 10.3390/nu15163634 ↗ |
| Topic | General aging biology & healthspan |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Alpha-Lipoic Acid (ALA)
The best-supported clinical use of ALA is for symptomatic diabetic peripheral neuropathy: randomized trials and meta-analyses, including the SYDNEY 2 and ALADIN programs, indicate that intravenous and oral ALA can reduce neuropathic pain, burning and numbness, with 600 mg/day identified as the optimal dose, although…
Alpha-lipoic acid (ALA), also called thioctic acid, is a naturally occurring sulfur-containing compound…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). What are the effects of orally administered alpha-lipoic acid (ALA) compared to a placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN), and what is the optimal dosage? [Plain-English summary of Nutrients 2023, PMID 37630823, DOI 10.3390/nu15163634]. Magellan Longevity. https://magellanlongevity.com/study/s129.html@misc{magellan_s129,
title = {What are the effects of orally administered alpha-lipoic acid (ALA) compared to a placebo in patients with diabetic sensorimotor peripheral neuropathy (DSPN), and what is the optimal dosage?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/s129.html}},
note = {Plain-English summary of PubMed PMID 37630823; DOI 10.3390/nu15163634; Nutrients 2023. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/s129.htmlRelated studies in the Magellan library
- Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral NeuropathyEndocr Metab Immune Disord Drug Targets · 2020 · PMID 32370731
- Examining oxidative stress as a mechanistic link between sleep irregularity and cardiovascular…Am J Physiol Heart Circ Physiol · 2026 · PMID 41740185
- Assessment of Noninvasive Oxygen Saturation During Pulmonary Rehabilitation: Smartwatch versus…Respir Care · 2023 · PMID 37193599
- A randomized controlled trial comparing myoinositol with metformin versus metformin…Clin Endocrinol (Oxf) · 2023 · PMID 37265016
- Taurine as a biomarker for aging: A new avenue for translational researchAdv Biomark Sci Technol · 2023 · PMID 38435677
- What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS)…Reprod Biol Endocrinol · 2023 · PMID 36703143
All 25 Magellan summaries on general aging biology & healthspan →
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →